NDA 219491 · Entasis Therap
Nuzolvence
Zoliflodacin · Oral
NovelPriority reviewCDER novel approval, Dec 12, 2025: To treat uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae
Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Dec 12, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
1 Phase 3, 0 recruiting
FAERS reports
9
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 13, 2026.
NUZOLVENCE is a spiropyrimidinetrione bacterial type II topoisomerase inhibitor indicated for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg. ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZOLVENCE and other antibacterial drugs, NUZOLVENCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Uncomplicated Urogenital Gonorrhea NUZOLVENCE is indicated for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg [see Clinical Studies (14) ]. 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZOLVENCE and other antibacterial drugs, NUZOLVENCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: NUZOLVENCE is an antibacterial drug [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- NUZOLVENCE · ZOLIFLODACIN 3GM/PACKET · FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zoliflodacin" as an intervention, any sponsor and status, largest first.
- Zoliflodacin in Uncomplicated GonorrhoeaPivotal-lookingCompleted
Global Antibiotics Research and Development PartnershipAcademic, hospital or other
NCT03959527 · 1,011 participants · Start Nov 6, 2019 · Primary completion Aug 30, 2023
Drug: zoliflodacin; ceftriaxone and 1 more · For: Gonorrhea
Sites: Birmingham, Alabama; San Francisco, California; Indianapolis, Indiana · 17 sites in all
- Study to Evaluate the Effect of Zoliflodacin on Testicular Function in Healthy Adult MenPivotal-lookingNot yet recruiting
Global Antibiotics Research and Development PartnershipAcademic, hospital or other
NCT07640477 · 200 participants (planned) · Start Dec 2026 · Primary completion Nov 2027
Drug: Zoliflodacin; Placebo · For: Testicular Abnominalies
Sites: Berlin, Germany; London, United Kingdom
- Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of GonorrheaPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02257918 · 180 participants · Start Nov 25, 2014 · Primary completion Dec 30, 2015
Drug: AZD0914; Ceftriaxone · For: Gonorrhoea
Sites: Birmingham, Alabama; Indianapolis, Indiana; New Orleans, Louisiana · 5 sites in all
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01929629 · 100 participants · Start Sep 2013 · Primary completion Mar 2014
Drug: Part A; Part B · For: Gonococcal (GC) Infection
Sites: Overland Park, Kansas
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT03613649 · 72 participants · Start Sep 25, 2018 · Primary completion Jan 2, 2019
Drug: AZD0914; Moxifloxacin · For: Electrocardiogram Repolarisation Abnormality; Gonococcal Infection
Sites: Overland Park, Kansas
Global Antibiotics Research and Development PartnershipAcademic, hospital or other
NCT05635305 · 50 participants · Start Nov 9, 2022 · Primary completion Feb 7, 2023
Drug: Zoliflodacin Patheon · For: Healthy Volunteers
Sites: Berlin, Germany
Drugs for Neglected DiseasesAcademic, hospital or other
NCT03718806 · 48 participants · Start Oct 3, 2018 · Primary completion Nov 12, 2018
Drug: Zoliflodacin · For: Gonorrhea
Sites: Miami, Florida
- Pharmacokinetics of Oral Zoliflodacin 3 g in Healthy Lactating WomenNot yet recruiting
Global Antibiotics Research and Development PartnershipAcademic, hospital or other
NCT07926997 · 10 participants (planned) · Start Dec 2026 · Primary completion Jun 2027
Drug: Zoliflodacin · For: Lactation
Sites: Las Vegas, Nevada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction9
- headache1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea.
Taylor SN, Marrazzo J, Batteiger BE, et al. · N Engl J Med 2018 · Clinical Trial, Phase II, Multicenter Study
- Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.
Luckey A, Balasegaram M, Barbee LA, et al. · Lancet 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018.
Unemo M, Ahlstrand J, Sánchez-Busó L, et al. · J Antimicrob Chemother 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Microbiological analysis and whole-genome sequencing of Neisseria gonorrhoeae from the microbiological failures in the international, zoliflodacin, phase 3, clinical trial for treatment of uncomplicated urogenital gonorrhoea: a retrospective, genomic, observational study.
Unemo M, Golparian D, Elango V, et al. · Lancet Microbe 2026 · Observational Study, Clinical Trial, Phase III
- GyrB in silico mining in 27 151 global gonococcal genomes from 1928-2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility.
Golparian D, Jacobsson S, Sánchez-Busó L, et al. · J Antimicrob Chemother 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Treatment efficacy for rectal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials.
Lo FWY, Kong FYS, Hocking JS · J Antimicrob Chemother 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Entasis Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.